BRAF V600E expression in langerhans cell histiocytosis: Clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases

American Journal of Surgical Pathology

Volumn 38, Issue 4, 2014, Pages 548-551

  Roden, Anja C ^a   Hu, Xiaowen ^a   Kip, Sertac ^a   Parrilla Castellar, Edgardo R ^a   Rumilla, Kandelaria M ^a   Vrana, Julie A ^a   Vassallo, Robert ^b   Ryu, Jay H ^b   Yi, Eunhee S ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

^b MAYO CLINIC   (United States)

Author keywords

BRAF V600E; Clonal; Langerhans cell histiocytosis; Pulmonary; Smoking

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADULT; ARTICLE; BIOSYNTHESIS; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL HISTIOCYTOSIS; LUNG DISEASE; MALE; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; SMOKING;

ADULT; DNA MUTATIONAL ANALYSIS; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG DISEASES; MALE; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SMOKING;

EID: 84896634002     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000129     Document Type: Article

References (23)

1. Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood. 2001;97: 1241-1248.
2. Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med. 2007; 4:e253.
3. Lieberman PH, Jones CR, Steinman RM, et al. Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years. Am J Surg Pathol. 1996;20:519-552.
4. Willman CL, Busque L, Griffith BB, et al. Langerhans'-cell histiocytosis (histiocytosis X)-A clonal proliferative disease. N Engl J Med. 1994;331:154-160.
5. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919-1923.
6. Kilpatrick SE, Wenger DE, Gilchrist GS, et al. Langerhans' cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer. 1995;76:2471-2484.
7. Yousem SA, Colby TV, Chen YY, et al. Pulmonary Langerhans' cell histiocytosis: Molecular analysis of clonality. Am J Surg Pathol. 2001;25:630-636.
8. Vassallo R, Ryu JH, Schroeder DR, et al. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med. 2002;346:484-490.
9. Chaowalit N, Pellikka PA, Decker PA, et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc. 2004;79: 1269-1275.
10. Yousem SA, Dacic S, Nikiforov YE, et al. Pulmonary Langerhans cell histiocytosis: Profiling of multifocal tumors using nextgeneration sequencing identifies concordant occurrence of BRAF V600E mutations. Chest. 2013;143:1679-1684.
11. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. 2002;25:511-518.
12. Pritchard C, Carragher L, Aldridge V, et al. Mouse models for BRAF-induced cancers. Biochem Soc Trans. 2007;35:1329-1333.
13. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
14. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
15. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121:1495-1500.
16. Busam KJ, Hedvat C, Pulitzer M, et al. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol. 2013;37:413-420.
17. Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012;120:e28-e34.
18. Gong L, Zhang WD, Li YH, et al. Clonal status and clinicopathological features of Langerhans cell histiocytosis. J Int Med Res. 2010;38:1099-1105.
19. Yu RC, Chu C, Buluwela L, et al. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet. 1994;343:767-768.
20. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29:2046-2051.
21. Sasaki H, Shitara M, Yokota K, et al. Braf and erbB2 mutations correlate with smoking status in lung cancer patients. Exp Ther Med. 2012;3:771-775.
22. Limsui D, Vierkant RA, Tillmans LS, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010;102:1012-1022.
23. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714.